ACM
IOVA icon

Atika Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Atika Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-160,000
Closed -$4.79M – 105
2020
Q1 		$4.79M Buy
+160,000
New +$4.24M 0.92% 35

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Atika Capital Management's IOVA Position: Q2 2020 in Review

Atika Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2020, closing a stake of 131,500 shares — an estimated $3.94M sold.

Atika Capital Management first reported a position in IOVA in Q2 2019 and held it in 2 quarters. The position peaked at $4.54M in Q2 2019. 257 funds tracked by Wall St. Rank hold IOVA as of Q2 2020.

  • Atika Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • Atika Capital Management sold 131,500 Iovance Biotherapeutics shares in Q2 2020, an estimated $3.94M.
  • Atika Capital Management first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 2 quarters.
  • Atika Capital Management's Iovance Biotherapeutics position peaked at $4.54M in Q2 2019.
  • 257 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2020.

Based on Atika Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.